References
- Ehrlich P. On Immunity with Special Reference to Cell Life: Croonian Lecture. Proceedings of the Royal Society (London) 1900; 66: 424–448
- Galton D AG, Israels L G, Nabarro J DN, Till M. Clinical Trial of p-(dichlorethylamine )phenyl butyric acid (CB1348) in malignant lymphoma. BMJ 1955; ii: 1172–1186
- Hiddemann W, Buske C, Dreyling M, Weigert O, Lenz G, Unterhalt M. Current management of follicular lymphomas. Br J Haematol 200; 136: 191–202
- Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495–497
- Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332: 323–327
- Hale G, Dyer M J, Clark M R, Phillips J M, Marcus R, Riechmann L, Winter G, Waldmann H. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988; 2: 1394–1399
- Maloney D G, Grillo-López A J, White C A. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188–2195
- Marcus R. Use of rituximab in patients with follicular lymphoma. Clin Oncol 2007; 19: 38–49
- Press O W, Unger J M, Braziel R M, Maloney D G, Miller T P, Leblanc M, Fisher R I. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006; 24: 4143–4149
- Weigert O, Illidge T, Hiddemann W, Dreyling M. Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma. Cancer 2006; 107: 686–695